The 18th International Myeloma Workshop (IMW) will be held in Vienna, Austria, as well as online as a virtual event, from September 8-11, 2021. The IMW meeting brings together leading experts in the field of multiple myeloma to present the latest research in the field, from the identification of potential new myeloma drug targets to updates from key clinical trials.

View all videos

IMW 2021

08–11 September 2021 | Vienna, Austria

View all videos

VJHemOnc @VJHemOnc ·

7 Jan 2008818437091365154

At #ASH25, @tamaciro shared updated results from the Phase II RESTORE trial evaluating elritercept in combination with ruxolitinib in patients with #myelofibrosis and anemia.

Find out more by clicking here:

👉 👈

#MPNsm #TrialUpdate #CTSM #HemOnc

Updates from the RESTORE trial of elritercept plus ruxolitinib in patients with MF and anemia

Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the updated results from the Phase II RESTORE...

ow.ly

Reply on Twitter 2008818437091365154 Retweet on Twitter 2008818437091365154 1 Like on Twitter 2008818437091365154 2 View Tweet 2008818437091365154

VJHemOnc @VJHemOnc ·

6 Jan 2008599570398281923

It was great to speak with @LuskinMarlise of @DanaFarber at #ASH25, who discussed a Phase I study that combined venetoclax and inotuzumab ozogamicin for the treatment of R/R ALL.🩸

Click here to watch: 👉

#ALLsm #Leusm #HemOnc #ImmunoOnc #CTSM

A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL

Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT05016947) that combi...

ow.ly

Reply on Twitter 2008599570398281923 Retweet on Twitter 2008599570398281923 0 Like on Twitter 2008599570398281923 5 View Tweet 2008599570398281923

VJHemOnc @VJHemOnc ·

6 Jan 2008463674130694254

In a recent interview, @MattReesMD provided insight into a multicenter retrospective study assessing the safety & efficacy of BCMA-directed CAR-T in patients with systemic AL #amyloidosis & concurrent #MultipleMyeloma.

Watch it here: 👉

#MMSM #Myeloma

Evaluating the real-world safety and efficacy of BCMA-directed CAR-T in systemic AL amyloidosis

Matthew Rees, MD, St. Vincent's Hospital, Melbourne, Australia, provides insight into a multicenter retrospective study ...

ow.ly

Reply on Twitter 2008463674130694254 Retweet on Twitter 2008463674130694254 4 Like on Twitter 2008463674130694254 7 View Tweet 2008463674130694254

VJHemOnc @VJHemOnc ·

5 Jan 2008222221588652463

🚨On December 23, 2025, the FDA approved mitapivat for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, based on data from the ENERGIZE & ENERGIZE-T trials.

Find out more about the approval here:

🗞️ 👉 https://ow.ly/gohh50XRPCq

Reply on Twitter 2008222221588652463 Retweet on Twitter 2008222221588652463 2 Like on Twitter 2008222221588652463 6 View Tweet 2008222221588652463

VJHemOnc @VJHemOnc ·

5 Jan 2008093664401101110

Want to hear about a trial investigating huCART19-IL18, an IL18-armored CAR T-cell product, in patients with CLL/SLL and Richter’s transformation?💉🩸

Watch our interview from #ASH25 with Jakub Svoboda of @PennMedicine here:

👉 👈

#CLLsm #Leusm #CTSM

huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure

Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, provides insight into a trial ...

ow.ly